NIKKEI 225
29,839.71-660.34(-2.17%)HANG SENG
24,073.80-25.34(-0.11%)CRUDE OIL
71.13+0.84(+1.20%)GOLD FUTURES
1,763.20-0.60(-0.03%)DOW
33,970.47-614.41(-1.78%)BTC-GBP
32,565.74-2,671.21(-7.58%)
Novo Nordisk A/S (NOVO-B.CO)
| Previous close | 643.40 |
| Open | 639.20 |
| Bid | 634.40 x 0 |
| Ask | 634.40 x 0 |
| Day's range | 625.10 - 644.90 |
| 52-week range | 406.90 - 684.50 |
| Volume | 2,152,185 |
| Avg. volume | 1,866,470 |
| Market cap | 1.457T |
| Beta (5Y monthly) | 0.27 |
| PE ratio (TTM) | 34.48 |
| EPS (TTM) | 18.40 |
| Earnings date | N/A |
| Forward dividend & yield | 9.35 (1.45%) |
| Ex-dividend date | 16 Aug 2021 |
| 1y target est | N/A |
- Globe Newswire
Novo Nordisk A/S – Share repurchase programme
Novo Nordisk A/S – Share repurchase programme Bagsværd, Denmark, 20 September 2021 – On 4 August 2021, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 18 billion to be executed during a 12-month period
- Motley Fool
2 Top Healthcare Stocks That Could Boost Your Portfolio in September (and Beyond)
These two companies have outperformed the market in the past year, and they are likely to continue doing so.
- Zacks
Here's Why Novo Nordisk (NVO) is a Strong Growth Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
